Goodwin advised Invicro LLC, a leading provider of imaging services and software for research and drug development, in their agreement to be acquired by Japanese-based Konica Minolta. No financial terms were disclosed.
Invicro’s business operations will continue as usual. No changes will be made to Invicro’s management structure, and Dr. Hoppin will stay on as CEO. Invicro remains committed to excellent service and scientific collaboration for sponsors while expanding the firm’s translational offering in medical imaging to pathology and genomics by joining Konica Minolta’s precision medicine platform.
Invicro is a global Contract Research Organization providing imaging services to the pharmaceutical and biotechnology industry from early phase discovery through late-phase clinical trials. Invicro built these services on a software and analytics platform enabling streamlined large-scale data analytics across any quantitative biomarker readout.
Headquartered in Tokyo, Konica Minolta, Inc. is a global digital technology company with core strengths in imaging and data analysis, optics, materials and nano-fabrication. The company creates products and digital solutions for the betterment of business and society. Konica Minolta operates in more than 50 countries and has more than 43,000 employees serving approximately two million customers in over 150 countries. The company is listed on the Tokyo Stock Exchange under the symbol TOKYO:4902.
The Goodwin team was led by partners Stuart Cable and David Henken and associates Eric Carlson and Evan Segal and included partners Stephen Charkoudian, Daniel Karelitz, Natascha George, Andrea Murino, Richard Matheny, Bradford Smith and Andrew Sucoff; senior attorney Ai Tajima; counsel Brian Mukherjee, Stephanie Philbin, Jacqueline Klosek and Jacob Osborn; and associates Brian Fleming, Rachel Mitchell Smith, Kyle Pine and Monica Patel.
For additional details on the transaction, please read the press release.